TL;DR
This study demonstrates that the loss of microRNA (miRNA) biogenesis, specifically through the deletion of the DGCR8 gene, drives the development of angiosarcoma (AS), a rare and aggressive cancer. Furthermore, the repurposed antibiotic enoxacin (ENX) shows therapeutic potential by enhancing miRNA processing, reducing AS cell viability and migration, and downregulating key oncogenic pathways.
What Problem Does This Paper Address?
Angiosarcoma (AS) is a highly aggressive vascular cancer with a poor prognosis and high metastatic rate. The underlying molecular mechanisms driving AS development and progression are not fully understood. Previous research from the authors' lab indicated that the loss of Dicer1, a crucial enzyme in miRNA processing, could lead to AS in mice, suggesting that miRNAs might act as tumor suppressors. This paper aims to further investigate this hypothesis by examining the role of DGCR8, another essential component of miRNA biogenesis, and to explore the therapeutic potential of enoxacin (ENX) in restoring miRNA function and combating AS.
Methods
The researchers employed a conditional knockout mouse model by deleting the Dgcr8 gene in endothelial cells using the aP2-Cre driver. This approach allowed them to specifically investigate the consequences of impaired miRNA biogenesis on AS development. They utilized various molecular biology techniques, including:
- Genomic PCR: To confirm the deletion of the Dgcr8 gene.
- Immunohistochemistry (IHC): To identify endothelial markers and confirm the tumor's origin.
- RT-PCR and qRT-PCR: To measure gene and miRNA expression levels.
- Cell viability assays (CellTiter-Glo): To assess the impact of ENX on AS cell survival.
- Caspase 3/7 activity assays: To measure apoptosis induction.
- Clonogenic colony formation assays: To evaluate the ability of AS cells to form colonies.
- Transwell migration assays: To assess cell migration capabilities.
- Small RNA-seq and mRNA-seq: To comprehensively analyze miRNA and mRNA expression profiles in response to ENX treatment.
- Luciferase reporter assays: To confirm ENX's effect on miRNA processing.
Datasets
The study utilized publicly available transcriptomic data from a previously generated aP2-Cre;Dicer1<sup>Flox/Flox</sup> (ADCKO) mouse model (GSE85834) for comparative analysis. The RNA-sequencing data generated in this study for SVR and ADC106 cells treated with ENX or DMSO have been deposited in the Gene Expression Omnibus (GEO) under accession numbers GSE298851 and GSE298666.
Key Insights and Ideas
- DGCR8 loss mirrors Dicer1 loss in AS development: The conditional deletion of Dgcr8 in endothelial cells recapitulates the angiosarcoma phenotype observed with Dicer1 loss, strongly implicating global miRNA deficiency as a driver of AS. This suggests that the entire miRNA biogenesis pathway is critical for suppressing AS.
- Endothelial cells are uniquely sensitive to miRNA loss: Unlike many other cell types where DICER1 acts as a haploinsufficient tumor suppressor, endothelial cells appear to be uniquely susceptible to the transformative effects of both Dicer1 and Dgcr8 biallelic deletion, leading to aggressive AS.
- Enoxacin as a potential therapeutic: The repurposed antibiotic enoxacin (ENX) demonstrates significant anti-AS activity by enhancing miRNA processing, reducing cell viability, migration, and clonogenicity, and inducing apoptosis in AS cells. This highlights ENX's potential as a therapeutic agent for AS.
- ENX restores tumor-suppressive miRNAs: ENX treatment leads to an increase in the abundance of several known tumor-suppressive miRNAs, including members of the let-7 family, miR-126, and miR-497 family, which are crucial for regulating oncogenic pathways.
- ENX targets oncogenic pathways: The drug effectively downregulates key oncogenic pathways involved in cell cycle progression, angiogenesis, and cell migration, which are often dysregulated in AS.
Key Results
- Conditional deletion of Dgcr8 in aP2-Cre mice led to spontaneous angiosarcoma development with a median tumor-free survival of 266 days.
- ENX treatment significantly reduced viability and increased apoptosis in various AS cell lines (ADC106, SVR, KU-CAS3, KU-CAS5) at concentrations between 100-220 µM.
- ENX treatment also reduced clonogenic colony formation and migration ability of AS cells.
- RNA-seq analysis revealed that ENX treatment altered the expression of 1689 and 3733 mRNAs in ADC106 and SVR cells, respectively.
- A significant number of miRNAs were differentially expressed upon ENX treatment, with a majority being upregulated, including known tumor suppressors.
- Gene ontology analysis of downregulated genes in ENX-treated cells showed enrichment in pathways related to cell cycle, angiogenesis, and vascular development.
Limitations and Future Work
The precise mechanism by which enoxacin enhances miRNA processing remains unclear, although it is thought to involve interactions with TRBP and DICER1. While genetic studies suggest DICER1 is required for ENX effects, the exact role of TRBP is still debated. The study primarily focused on in vitro and mouse models; therefore, future work should involve comprehensive in vivo studies to confirm the therapeutic benefits of ENX in AS models. Further mechanistic investigations are needed to fully elucidate the complex interactions and pathways affected by ENX and to explore its potential as a monotherapy or in combination with other treatments for AS. The authors also suggest that future studies should investigate the individual and combined functions and mechanisms of the miRNAs upregulated by ENX.
Summary updated